<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02034409</url>
  </required_header>
  <id_info>
    <org_study_id>CLIN-006-13S</org_study_id>
    <secondary_id>CXI01CX000954-01A1</secondary_id>
    <nct_id>NCT02034409</nct_id>
  </id_info>
  <brief_title>A Pilot Trial to Assess Low-Intensity Ultrasound in Osteoarthritis</brief_title>
  <acronym>PLUS+OA</acronym>
  <official_title>A Pilot Trial to Assess Low-Intensity Ultrasound in Osteoarthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this exploratory trial is to investigate whether PLIUS is potentially&#xD;
      effective as a disease and symptom modifying intervention in patients with early knee OA.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Osteoarthritis (OA), the most common form of arthritis, is a prevalent and debilitating&#xD;
      disease without therapies that alter disease progress and is currently managed with&#xD;
      symptom-modifying therapies that are only modestly effective. In spite of substantial&#xD;
      progress in understanding the pathogenesis of OA, no effective disease modifying&#xD;
      interventions have been established. Degenerative joint cartilage is a central feature of OA,&#xD;
      yet joint cartilage has a limited capacity for repair. Results from animal research&#xD;
      demonstrate that pulsed low intensity ultrasound (PLIUS) mechanically stimulates, and may&#xD;
      promote, cartilage repair. This exploratory trial will investigate whether PLIUS is&#xD;
      potentially effective as a disease and symptom modifying intervention in patients with early&#xD;
      knee OA.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 22, 2015</start_date>
  <completion_date type="Actual">September 30, 2020</completion_date>
  <primary_completion_date type="Actual">June 1, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants in this double-blind, randomized, sham-controlled trial will be randomly assigned to receive either sham or PLIUS device for 48 weeks.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Co-Primary Measure: a) Symptom Reduction: OMERACT-OARSI Treatment Responsiveness</measure>
    <time_frame>48 weeks</time_frame>
    <description>Outcome Measures in Rheumatology Clinical Trials- Osteoarthritis Research Society International (OMERACT-OARSI) Response incorporates changes in pain and global assessment to define response in OA clinical trials. A response is classified as: 1) An improvement in either pain or function of at least 50 percent accompanied by an absolute decrease of at least 20 mm on the visual-analogue scale for pain or function, OR 2) The occurrence of at least two of the following: a) a decrease in pain of at least 20 percent accompanied by a decrease of at least 10 mm on the visual-analogue scale; b) an improvement in function of at least 20 percent and a decrease of at least 10 mm on the visual-analogue scale; c) an increase in the patient's global assessment score by at least 20 percent accompanied by a decrease of at least 10 mm on the visual-analogue scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Co-Primary Measure: b) Disease Modification as Measured by Change From Baseline in Cartilage Thickness of the Central Medial Femoral Condyle Disease</measure>
    <time_frame>Baseline, 48 weeks</time_frame>
    <description>The study has been designed to determine if PLIUS potentially diminishes articular cartilage thinning by measuring cartilage thickness in the tibial femoral joint. The measure selected to best evaluate this is cartilage thickness of the central medial femoral condyle because studies of the OAI (Osteoarthritis Initiative) data have shown this region to be among those most sensitive to change and, due to the anatomical positioning of the device, the most likely to be affected by treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in WOMAC Stiffness Subscale Score</measure>
    <time_frame>Baseline, week 24, week 48</time_frame>
    <description>The WOMAC® Index questionnaire is a tri-dimensional, disease-specific, self-administered, health status measure. It probes clinically important, patient-relevant symptoms in the areas of pain, stiffness and physical function in patients with osteoarthritis of the hip and/or knee. The WOMAC has been linguistically validated and is a reliable and responsive measure of outcome, and has been used in diverse clinical and interventional environments. Range is from 0 - 200. The higher the score, the worse the symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in WOMAC Pain Subscale Score</measure>
    <time_frame>Baseline, week 24, week 48</time_frame>
    <description>The WOMAC® Index questionnaire [33] is a tri-dimensional, disease-specific, self-administered, health status measure. It probes clinically important, patient-relevant symptoms in the areas of pain, stiffness and physical function in patients with osteoarthritis of the hip and/or knee. The WOMAC has been linguistically validated and is a reliable and responsive measure of outcome, and has been used in diverse clinical and interventional environments. WOMAC pain scores from 0-500 mm. The higher the score, the worse the symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in WOMAC Functional Limits Subscale Score</measure>
    <time_frame>Baseline, week 24, week 48</time_frame>
    <description>The WOMAC® Index questionnaire [33] is a tri-dimensional, disease-specific, self-administered, health status measure. It probes clinically important, patient-relevant symptoms in the areas of pain, stiffness and physical function in patients with osteoarthritis of the hip and/or knee. The WOMAC has been linguistically validated and is a reliable and responsive measure of outcome, and has been used in diverse clinical and interventional environments. Range is from 0 - 1700. The higher the score, the worse the symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Total WOMAC Score</measure>
    <time_frame>Baseline, week 24, week 48</time_frame>
    <description>The WOMAC® Index questionnaire is a tri-dimensional, disease-specific, self-administered, health status measure. It probes clinically important, patient-relevant symptoms in the areas of pain, stiffness and physical function in patients with osteoarthritis of the hip and/or knee. The WOMAC has been linguistically validated and is a reliable and responsive measure of outcome, and has been used in diverse clinical and interventional environments. Range is from 0 - 2400. The higher the score, the worse the symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Patient Global Assessment of Disease Status</measure>
    <time_frame>Baseline, week 24, week 48</time_frame>
    <description>A patient global assessment of disease status on a Visual Analog Scale (VAS) will be measured at each clinic visit. Patients will be asked to quantify their disease status on a 100 mm VAS as follows: &quot;Considering all the ways your arthritis of the knee affects you, mark 'X' on the scale for how well you are doing.&quot; The scale shows the left hand marker &quot;Very Well&quot;, and the right hand marker &quot;Very Poor.&quot; Range 0 to 100 mm. The higher the score, the worse the symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Investigator Global Assessment of Disease Status</measure>
    <time_frame>Baseline, week 24, week 48</time_frame>
    <description>An investigator global assessment of disease status on a 100 mm VAS was measured at each clinic visit as follows: &quot;Make a global assessment of the patient's disease status, with regard to the index knee, by marking an 'X' on the scale below.&quot;, with left hand marker &quot;Very Well&quot; and right hand marker &quot;Very Poor.&quot; Range 0 to 100 mm. The higher the score, the worse the symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Intermittent and Constant Osteoarthritis Pain (ICOAP) Constant Pain Subscale</measure>
    <time_frame>Baseline, week 24, week 48</time_frame>
    <description>This 11-item tool is designed to assess pain in individuals with knee osteoarthritis taking into account both constant and intermittent pain experiences. This tool is designed to be interviewer-administered. Study participants are asked to respond to the questionnaire items based on index knee in the past week (i.e., past 7-day period). Study participants responded to all questions for the same joint. This tool is intended to be responsive to change in OA pain over time or with treatment. Range 0 to 100 mm. The higher the score, the worse the symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Intermittent and Constant Osteoarthritis Pain (ICOAP) Intermittent Pain Subscale</measure>
    <time_frame>Baseline, week 24, week 48</time_frame>
    <description>This 11-item tool is designed to assess pain in individuals with knee osteoarthritis taking into account both constant and intermittent pain experiences. This tool is designed to be interviewer-administered and takes less than 10 minutes to complete. Study participants will be asked to respond to the questionnaire items based on index knee in the past week (i.e., past 7-day period). Study participants will respond to all questions for the same joint. This tool is intended to be responsive to change in OA pain over time or with treatment. Range 0 to 100 mm. The higher the score, the worse the symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Intermittent and Constant Osteoarthritis Pain (ICOAP) Total Pain Score</measure>
    <time_frame>Baseline, week 24, week 48</time_frame>
    <description>This 11-item tool is designed to assess pain in individuals with knee osteoarthritis taking into account both constant and intermittent pain experiences. This tool is designed to be interviewer-administered and takes less than 10 minutes to complete. Study participants will be asked to respond to the questionnaire items based on index knee in the past week (i.e., past 7-day period). Study participants will respond to all questions for the same joint. This tool is intended to be responsive to change in OA pain over time or with treatment. Range 0 to 100 mm. The higher the score, the worse the symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Discontinuing the Study Device Due to an Adverse Device Event</measure>
    <time_frame>Baseline, 4, 8, 12, 24, 36, and 48-week visits</time_frame>
    <description>Difference between study groups in number of participants who discontinued usage of the study device due to adverse device events at 4, 8, 12, 24, 36, and 48-week visits.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">140</enrollment>
  <condition>Osteoarthritis, Degenerative</condition>
  <arm_group>
    <arm_group_label>Sham</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Treatment to index knee with sham device for 48 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PLIUS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment to index knee with PLIUS device for 48 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Pulsed Low Intensity Ultrasound</intervention_name>
    <description>20 minutes daily for 48 weeks</description>
    <arm_group_label>PLIUS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham Comparator</intervention_name>
    <description>20 minutes daily for 48 weeks</description>
    <arm_group_label>Sham</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  40 years of age or older, and a US Military Veteran&#xD;
&#xD;
          -  Clinical symptoms of osteoarthritis for at least 6 months&#xD;
&#xD;
          -  Pain in the index knee on motion or weight bearing for the majority of days during the&#xD;
             month before screening&#xD;
&#xD;
          -  Clinical diagnosis of primary osteoarthritis of the knee based on clinical and&#xD;
             radiographic criteria&#xD;
&#xD;
          -  American Rheumatism Association Functional Class I, II, or III&#xD;
&#xD;
          -  Females of childbearing potential must be willing to use a reliable form of medically&#xD;
             acceptable contraception&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Concurrent medical/arthritis condition(s), or any other illness per the opinion of the&#xD;
             investigator, that could interfere with the evaluation of pain or efficacy&#xD;
&#xD;
          -  Spine or hip pain of significant magnitude&#xD;
&#xD;
          -  History of significant ligament or meniscal injury of the index joint requiring&#xD;
             surgical repair&#xD;
&#xD;
          -  Arthroscopy of the index knee within 6 months of study entry&#xD;
&#xD;
          -  Unable to undergo MRI of the knee&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
&#xD;
          -  Corticosteroid treatment within 1 to 3 months prior to study entry&#xD;
&#xD;
          -  Intra-articular injection of hyaluronic acid or congeners to the index knee within 6&#xD;
             months of study entry&#xD;
&#xD;
          -  Use of excluded therapy(ies) prior to study entry&#xD;
&#xD;
          -  Use of disease modifying anti-rheumatic medications and chronic tetracycline or its&#xD;
             derivatives&#xD;
&#xD;
          -  Exposure to glucosamine, chondroitin sulfate, or any other investigational treatment,&#xD;
             within 1 month of study entry&#xD;
&#xD;
          -  Use of any medical therapy, complementary or alternative regimens for the treatment of&#xD;
             osteoarthritis within 7 days prior to study entry&#xD;
&#xD;
          -  Initiation of physical therapy or muscle conditioning program to the lower extremities&#xD;
             within 2 months within 2 months prior to study entry&#xD;
&#xD;
          -  Unlikely to comply with study requirements&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel O Clegg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VA Salt Lake City Health Care System, Salt Lake City, UT</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA San Diego Healthcare System, San Diego, CA</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92161</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA North Texas Health Care System Dallas VA Medical Center, Dallas, TX</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Salt Lake City Health Care System, Salt Lake City, UT</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84148</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>January 9, 2014</study_first_submitted>
  <study_first_submitted_qc>January 9, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2014</study_first_posted>
  <results_first_submitted>June 8, 2021</results_first_submitted>
  <results_first_submitted_qc>October 15, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">October 18, 2021</results_first_posted>
  <last_update_submitted>October 15, 2021</last_update_submitted>
  <last_update_submitted_qc>October 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Knee Osteoarthritis</keyword>
  <keyword>Pulsed Low Intensity Ultrasound</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 1, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/09/NCT02034409/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited at 2 medical centers between May 2015 and January 2019. The first participant was enrolled May 2017 and the last participant was enrolled in January 2019.</recruitment_details>
      <pre_assignment_details>140 participants began, and 136 completed, the 4-Week Sham Run-in Period. 4 of the 140 Sham Run-in participants were withdrawn due to being less than 80% treatment compliance.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Sham</title>
          <description>Treatment to index knee with sham device for 48 weeks&#xD;
ShamComparator: 20 minutes daily for 48 weeks</description>
        </group>
        <group group_id="P2">
          <title>PLIUS (Pulsed Low Intensity UltraSound)</title>
          <description>Treatment to index knee with PLIUS device for 48 weeks&#xD;
PLIUS device: 20 minutes daily for 48 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Sham Run-in Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="140"/>
                <participants group_id="P2" count="0">Number started is zero because there is no PLIUS arm in Sham Run-in Period</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="136"/>
                <participants group_id="P2" count="0">Number started is zero because there is no PLIUS arm in Sham Run-in Period</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Participants withdrawn per protocol because less than 80% treatment compliance</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Sham-Controlled Treatment Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="67">Number started in Sham Arm of Sham-Controlled Treatment Period Milestone not equal to Sham Run-in Period Milestone because participants in this Milestone are randomly assigned to either Sham or PLIUS treatment arm.</participants>
                <participants group_id="P2" count="69">Number started in PLIUS Arm of Sham-Controlled Treatment Period Milestone not equal to Sham Run-in Period Milestone because participants in this Milestone are randomly assigned to either Sham or PLIUS treatment arm.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
                <participants group_id="P2" count="54"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>misrandomized</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sham</title>
          <description>Treatment to index knee with sham device for 48 weeks&#xD;
Sham Comparator: 20 minutes daily for 48 weeks</description>
        </group>
        <group group_id="B2">
          <title>PLIUS</title>
          <description>Treatment to index knee with PLIUS device for 48 weeks&#xD;
Pulsed Low Intensity Ultrasound: 20 minutes daily for 48 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="65"/>
            <count group_id="B2" value="67"/>
            <count group_id="B3" value="132"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="65"/>
                    <count group_id="B2" value="67"/>
                    <count group_id="B3" value="132"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.4" spread="10.9"/>
                    <measurement group_id="B2" value="62.9" spread="10.5"/>
                    <measurement group_id="B3" value="63.6" spread="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="65"/>
                    <count group_id="B2" value="67"/>
                    <count group_id="B3" value="132"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="65"/>
                    <count group_id="B2" value="67"/>
                    <count group_id="B3" value="132"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="109"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="65"/>
                    <count group_id="B2" value="67"/>
                    <count group_id="B3" value="132"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="100"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="65"/>
                    <count group_id="B2" value="67"/>
                    <count group_id="B3" value="132"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                    <measurement group_id="B2" value="67"/>
                    <measurement group_id="B3" value="132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <description>Body Mass Index</description>
          <population>Needed data for baseline measure only available for 130 participants</population>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="64"/>
                    <count group_id="B2" value="66"/>
                    <count group_id="B3" value="130"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.6" spread="5.5"/>
                    <measurement group_id="B2" value="31.8" spread="5.4"/>
                    <measurement group_id="B3" value="31.7" spread="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Years with Osteoarthritis</title>
          <description>Participant reported duration of osteoarthritis</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="65"/>
                    <count group_id="B2" value="67"/>
                    <count group_id="B3" value="132"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11.7" spread="11.2"/>
                    <measurement group_id="B2" value="15.0" spread="13.2"/>
                    <measurement group_id="B3" value="13.4" spread="12.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>ARA Functional Class</title>
          <description>American Rheumatism Association (ARA) Functional Class categorize global functional capacity and is assessed by a qualified health professional. A higher class indicates a worsening of functional capacity.&#xD;
Class I - Completely able to perform usual activities of daily living. Class II - Able to perform usual self-care and vocational activities but limited in avocational activities.&#xD;
Class III - Able to perform usual self-care activities but limited in vocational and avocational activities.&#xD;
Class IV - Limited in ability to perform usual self-care, vocational, and avocational activities.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Class I</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="65"/>
                    <count group_id="B2" value="67"/>
                    <count group_id="B3" value="132"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Class II</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="65"/>
                    <count group_id="B2" value="67"/>
                    <count group_id="B3" value="132"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Class III</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="65"/>
                    <count group_id="B2" value="67"/>
                    <count group_id="B3" value="132"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Class IV</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="65"/>
                    <count group_id="B2" value="67"/>
                    <count group_id="B3" value="132"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Co-Primary Measure: a) Symptom Reduction: OMERACT-OARSI Treatment Responsiveness</title>
        <description>Outcome Measures in Rheumatology Clinical Trials- Osteoarthritis Research Society International (OMERACT-OARSI) Response incorporates changes in pain and global assessment to define response in OA clinical trials. A response is classified as: 1) An improvement in either pain or function of at least 50 percent accompanied by an absolute decrease of at least 20 mm on the visual-analogue scale for pain or function, OR 2) The occurrence of at least two of the following: a) a decrease in pain of at least 20 percent accompanied by a decrease of at least 10 mm on the visual-analogue scale; b) an improvement in function of at least 20 percent and a decrease of at least 10 mm on the visual-analogue scale; c) an increase in the patient's global assessment score by at least 20 percent accompanied by a decrease of at least 10 mm on the visual-analogue scale</description>
        <time_frame>48 weeks</time_frame>
        <population>Participants with baseline and 48 week values.</population>
        <group_list>
          <group group_id="O1">
            <title>Sham</title>
            <description>Treatment to index knee with sham device for 48 weeks&#xD;
Sham Comparator: 20 minutes daily for 48 weeks</description>
          </group>
          <group group_id="O2">
            <title>PLIUS</title>
            <description>Treatment to index knee with PLIUS device for 48 weeks&#xD;
Pulsed Low Intensity Ultrasound: 20 minutes daily for 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Co-Primary Measure: a) Symptom Reduction: OMERACT-OARSI Treatment Responsiveness</title>
          <description>Outcome Measures in Rheumatology Clinical Trials- Osteoarthritis Research Society International (OMERACT-OARSI) Response incorporates changes in pain and global assessment to define response in OA clinical trials. A response is classified as: 1) An improvement in either pain or function of at least 50 percent accompanied by an absolute decrease of at least 20 mm on the visual-analogue scale for pain or function, OR 2) The occurrence of at least two of the following: a) a decrease in pain of at least 20 percent accompanied by a decrease of at least 10 mm on the visual-analogue scale; b) an improvement in function of at least 20 percent and a decrease of at least 10 mm on the visual-analogue scale; c) an increase in the patient's global assessment score by at least 20 percent accompanied by a decrease of at least 10 mm on the visual-analogue scale</description>
          <population>Participants with baseline and 48 week values.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>OMERACT-OARSI responders</title>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="38"/>
                  </measurement_list>
                </category>
                <category>
                  <title>OMERACT-OARSI non-responders</title>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Sample size has been calculated with ranking and selection methodology, a procedure used for Phase II trials. The purpose of the procedure as applied to this study is to identify whether PLIUS has a high probability of being more effective than sham. This is accomplished by obtaining sample estimates of the outcome for the PLIUS and sham groups and determining whether the PLIUS group outcome is better by the pre-specified margin of difference.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>For the 48-week OMERACT-OARSI response the minimally clinically significant difference is an absolute rate difference of 10% between sham and PLIUS groups. With a total sample size of 144 the probability of correctly selecting the group with the greatest OORR is at least 0.885 assuming (δ=10%) that the sham group is drawn from a population with a 50% response rate and the PLIUS group is drawn from a population with response rate of at least 60% or at most 40%.</non_inferiority_desc>
            <other_analysis_desc>Since the ranking and selection procedures are fundamentally different from traditional hypothesis testing, concepts of statistical significance and power have no direct analogue.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Co-Primary Measure: b) Disease Modification as Measured by Change From Baseline in Cartilage Thickness of the Central Medial Femoral Condyle Disease</title>
        <description>The study has been designed to determine if PLIUS potentially diminishes articular cartilage thinning by measuring cartilage thickness in the tibial femoral joint. The measure selected to best evaluate this is cartilage thickness of the central medial femoral condyle because studies of the OAI (Osteoarthritis Initiative) data have shown this region to be among those most sensitive to change and, due to the anatomical positioning of the device, the most likely to be affected by treatment.</description>
        <time_frame>Baseline, 48 weeks</time_frame>
        <population>Participants with baseline and 48 week value</population>
        <group_list>
          <group group_id="O1">
            <title>Sham</title>
            <description>Treatment to index knee with sham device for 48 weeks&#xD;
Sham Comparator: 20 minutes daily for 48 weeks</description>
          </group>
          <group group_id="O2">
            <title>PLIUS</title>
            <description>Treatment to index knee with PLIUS device for 48 weeks&#xD;
Pulsed Low Intensity Ultrasound: 20 minutes daily for 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Co-Primary Measure: b) Disease Modification as Measured by Change From Baseline in Cartilage Thickness of the Central Medial Femoral Condyle Disease</title>
          <description>The study has been designed to determine if PLIUS potentially diminishes articular cartilage thinning by measuring cartilage thickness in the tibial femoral joint. The measure selected to best evaluate this is cartilage thickness of the central medial femoral condyle because studies of the OAI (Osteoarthritis Initiative) data have shown this region to be among those most sensitive to change and, due to the anatomical positioning of the device, the most likely to be affected by treatment.</description>
          <population>Participants with baseline and 48 week value</population>
          <units>μm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-42.2" spread="297.0"/>
                    <measurement group_id="O2" value="-73.8" spread="168.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Sample size has been calculated with ranking and selection methodology, a procedure used for Phase II trials. The purpose of the procedure as applied to this study is to identify whether PLIUS has a high probability of being more effective than sham. This is accomplished by obtaining sample estimates of the outcome for the PLIUS and sham groups and determining whether the PLIUS group outcome is better by the pre-specified margin of difference.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>For the 48-week cartilage change outcome measure the minimally clinically significant difference is 33 μm. With a difference of 33 μm, σ=152 μm standard deviation, k=2 groups, and P=0.90 probability to obtain τ=1.8124, which we use to estimate the per-group sample size: n=σ2(τ/δ*)2=72 or a total of 144.</non_inferiority_desc>
            <other_analysis_desc>Since the ranking and selection procedures are fundamentally different from traditional hypothesis testing, concepts of statistical significance and power have no direct analogue.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in WOMAC Stiffness Subscale Score</title>
        <description>The WOMAC® Index questionnaire is a tri-dimensional, disease-specific, self-administered, health status measure. It probes clinically important, patient-relevant symptoms in the areas of pain, stiffness and physical function in patients with osteoarthritis of the hip and/or knee. The WOMAC has been linguistically validated and is a reliable and responsive measure of outcome, and has been used in diverse clinical and interventional environments. Range is from 0 - 200. The higher the score, the worse the symptoms.</description>
        <time_frame>Baseline, week 24, week 48</time_frame>
        <population>Intent to Treat</population>
        <group_list>
          <group group_id="O1">
            <title>Sham</title>
            <description>Treatment to index knee with sham device for 48 weeks&#xD;
Sham Comparator: 20 minutes daily for 48 weeks</description>
          </group>
          <group group_id="O2">
            <title>PLIUS</title>
            <description>Treatment to index knee with PLIUS device for 48 weeks&#xD;
Pulsed Low Intensity Ultrasound: 20 minutes daily for 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in WOMAC Stiffness Subscale Score</title>
          <description>The WOMAC® Index questionnaire is a tri-dimensional, disease-specific, self-administered, health status measure. It probes clinically important, patient-relevant symptoms in the areas of pain, stiffness and physical function in patients with osteoarthritis of the hip and/or knee. The WOMAC has been linguistically validated and is a reliable and responsive measure of outcome, and has been used in diverse clinical and interventional environments. Range is from 0 - 200. The higher the score, the worse the symptoms.</description>
          <population>Intent to Treat</population>
          <units>Visual Analog Scale (mm)</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from Baseline to week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-33.6" lower_limit="-47.6" upper_limit="-19.7"/>
                    <measurement group_id="O2" value="-27.7" lower_limit="-40.2" upper_limit="-15.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-49.8" lower_limit="-64.6" upper_limit="-35.1"/>
                    <measurement group_id="O2" value="-37.1" lower_limit="-51.6" upper_limit="-22.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in WOMAC Pain Subscale Score</title>
        <description>The WOMAC® Index questionnaire [33] is a tri-dimensional, disease-specific, self-administered, health status measure. It probes clinically important, patient-relevant symptoms in the areas of pain, stiffness and physical function in patients with osteoarthritis of the hip and/or knee. The WOMAC has been linguistically validated and is a reliable and responsive measure of outcome, and has been used in diverse clinical and interventional environments. WOMAC pain scores from 0-500 mm. The higher the score, the worse the symptoms.</description>
        <time_frame>Baseline, week 24, week 48</time_frame>
        <population>Intent to Treat</population>
        <group_list>
          <group group_id="O1">
            <title>Sham</title>
            <description>Treatment to index knee with sham device for 48 weeks&#xD;
Sham Comparator: 20 minutes daily for 48 weeks</description>
          </group>
          <group group_id="O2">
            <title>PLIUS</title>
            <description>Treatment to index knee with PLIUS device for 48 weeks&#xD;
Pulsed Low Intensity Ultrasound: 20 minutes daily for 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in WOMAC Pain Subscale Score</title>
          <description>The WOMAC® Index questionnaire [33] is a tri-dimensional, disease-specific, self-administered, health status measure. It probes clinically important, patient-relevant symptoms in the areas of pain, stiffness and physical function in patients with osteoarthritis of the hip and/or knee. The WOMAC has been linguistically validated and is a reliable and responsive measure of outcome, and has been used in diverse clinical and interventional environments. WOMAC pain scores from 0-500 mm. The higher the score, the worse the symptoms.</description>
          <population>Intent to Treat</population>
          <units>Visual Analog Scale mm</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from Baseline to week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-84.2" lower_limit="-109.4" upper_limit="-58.9"/>
                    <measurement group_id="O2" value="-91.4" lower_limit="-111.1" upper_limit="-71.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-117.1" lower_limit="-146.2" upper_limit="-87.9"/>
                    <measurement group_id="O2" value="-93.4" lower_limit="-124.4" upper_limit="-62.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in WOMAC Functional Limits Subscale Score</title>
        <description>The WOMAC® Index questionnaire [33] is a tri-dimensional, disease-specific, self-administered, health status measure. It probes clinically important, patient-relevant symptoms in the areas of pain, stiffness and physical function in patients with osteoarthritis of the hip and/or knee. The WOMAC has been linguistically validated and is a reliable and responsive measure of outcome, and has been used in diverse clinical and interventional environments. Range is from 0 - 1700. The higher the score, the worse the symptoms.</description>
        <time_frame>Baseline, week 24, week 48</time_frame>
        <population>Intent to Treat</population>
        <group_list>
          <group group_id="O1">
            <title>Sham</title>
            <description>Treatment to index knee with sham device for 48 weeks&#xD;
Sham Comparator: 20 minutes daily for 48 weeks</description>
          </group>
          <group group_id="O2">
            <title>PLIUS</title>
            <description>Treatment to index knee with PLIUS device for 48 weeks&#xD;
Pulsed Low Intensity Ultrasound: 20 minutes daily for 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in WOMAC Functional Limits Subscale Score</title>
          <description>The WOMAC® Index questionnaire [33] is a tri-dimensional, disease-specific, self-administered, health status measure. It probes clinically important, patient-relevant symptoms in the areas of pain, stiffness and physical function in patients with osteoarthritis of the hip and/or knee. The WOMAC has been linguistically validated and is a reliable and responsive measure of outcome, and has been used in diverse clinical and interventional environments. Range is from 0 - 1700. The higher the score, the worse the symptoms.</description>
          <population>Intent to Treat</population>
          <units>Visual Analog Scale (mm)</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from Baseline to week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-285.2" lower_limit="-377.1" upper_limit="-193.2"/>
                    <measurement group_id="O2" value="-241.1" lower_limit="-316.9" upper_limit="-165.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-407.3" lower_limit="-510.8" upper_limit="-303.7"/>
                    <measurement group_id="O2" value="-283.1" lower_limit="-399.7" upper_limit="-166.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Total WOMAC Score</title>
        <description>The WOMAC® Index questionnaire is a tri-dimensional, disease-specific, self-administered, health status measure. It probes clinically important, patient-relevant symptoms in the areas of pain, stiffness and physical function in patients with osteoarthritis of the hip and/or knee. The WOMAC has been linguistically validated and is a reliable and responsive measure of outcome, and has been used in diverse clinical and interventional environments. Range is from 0 - 2400. The higher the score, the worse the symptoms.</description>
        <time_frame>Baseline, week 24, week 48</time_frame>
        <population>Intent to Treat</population>
        <group_list>
          <group group_id="O1">
            <title>Sham</title>
            <description>Treatment to index knee with sham device for 48 weeks&#xD;
Sham Comparator: 20 minutes daily for 48 weeks</description>
          </group>
          <group group_id="O2">
            <title>PLIUS</title>
            <description>Treatment to index knee with PLIUS device for 48 weeks&#xD;
Pulsed Low Intensity Ultrasound: 20 minutes daily for 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Total WOMAC Score</title>
          <description>The WOMAC® Index questionnaire is a tri-dimensional, disease-specific, self-administered, health status measure. It probes clinically important, patient-relevant symptoms in the areas of pain, stiffness and physical function in patients with osteoarthritis of the hip and/or knee. The WOMAC has been linguistically validated and is a reliable and responsive measure of outcome, and has been used in diverse clinical and interventional environments. Range is from 0 - 2400. The higher the score, the worse the symptoms.</description>
          <population>Intent to Treat</population>
          <units>Visual Analog Scale (mm)</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from Baseline to week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-403.0" lower_limit="-527.3" upper_limit="-278.6"/>
                    <measurement group_id="O2" value="-360.2" lower_limit="-460.8" upper_limit="-259.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-574.1" lower_limit="-713.8" upper_limit="-434.4"/>
                    <measurement group_id="O2" value="-413.6" lower_limit="-571.4" upper_limit="-255.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Patient Global Assessment of Disease Status</title>
        <description>A patient global assessment of disease status on a Visual Analog Scale (VAS) will be measured at each clinic visit. Patients will be asked to quantify their disease status on a 100 mm VAS as follows: &quot;Considering all the ways your arthritis of the knee affects you, mark 'X' on the scale for how well you are doing.&quot; The scale shows the left hand marker &quot;Very Well&quot;, and the right hand marker &quot;Very Poor.&quot; Range 0 to 100 mm. The higher the score, the worse the symptoms.</description>
        <time_frame>Baseline, week 24, week 48</time_frame>
        <population>Intent to Treat</population>
        <group_list>
          <group group_id="O1">
            <title>Sham</title>
            <description>Treatment to index knee with sham device for 48 weeks&#xD;
Sham Comparator: 20 minutes daily for 48 weeks</description>
          </group>
          <group group_id="O2">
            <title>PLIUS</title>
            <description>Treatment to index knee with PLIUS device for 48 weeks&#xD;
Pulsed Low Intensity Ultrasound: 20 minutes daily for 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Patient Global Assessment of Disease Status</title>
          <description>A patient global assessment of disease status on a Visual Analog Scale (VAS) will be measured at each clinic visit. Patients will be asked to quantify their disease status on a 100 mm VAS as follows: &quot;Considering all the ways your arthritis of the knee affects you, mark 'X' on the scale for how well you are doing.&quot; The scale shows the left hand marker &quot;Very Well&quot;, and the right hand marker &quot;Very Poor.&quot; Range 0 to 100 mm. The higher the score, the worse the symptoms.</description>
          <population>Intent to Treat</population>
          <units>Visual Analog Scale (mm)</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from Baseline to Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.6" lower_limit="-23.3" upper_limit="-9.9"/>
                    <measurement group_id="O2" value="-15.0" lower_limit="-21.4" upper_limit="-8.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.7" lower_limit="-30.8" upper_limit="-16.5"/>
                    <measurement group_id="O2" value="-17.6" lower_limit="-26.3" upper_limit="-9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Investigator Global Assessment of Disease Status</title>
        <description>An investigator global assessment of disease status on a 100 mm VAS was measured at each clinic visit as follows: &quot;Make a global assessment of the patient's disease status, with regard to the index knee, by marking an 'X' on the scale below.&quot;, with left hand marker &quot;Very Well&quot; and right hand marker &quot;Very Poor.&quot; Range 0 to 100 mm. The higher the score, the worse the symptoms.</description>
        <time_frame>Baseline, week 24, week 48</time_frame>
        <population>Intent to Treat</population>
        <group_list>
          <group group_id="O1">
            <title>Sham</title>
            <description>Treatment to index knee with sham device for 48 weeks&#xD;
Sham Comparator: 20 minutes daily for 48 weeks</description>
          </group>
          <group group_id="O2">
            <title>PLIUS</title>
            <description>Treatment to index knee with PLIUS device for 48 weeks&#xD;
Pulsed Low Intensity Ultrasound: 20 minutes daily for 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Investigator Global Assessment of Disease Status</title>
          <description>An investigator global assessment of disease status on a 100 mm VAS was measured at each clinic visit as follows: &quot;Make a global assessment of the patient's disease status, with regard to the index knee, by marking an 'X' on the scale below.&quot;, with left hand marker &quot;Very Well&quot; and right hand marker &quot;Very Poor.&quot; Range 0 to 100 mm. The higher the score, the worse the symptoms.</description>
          <population>Intent to Treat</population>
          <units>Visual Analog Scale (mm)</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from Baseline to Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.4" lower_limit="-25.0" upper_limit="-11.9"/>
                    <measurement group_id="O2" value="-15.8" lower_limit="-22.5" upper_limit="-9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.6" lower_limit="-36.6" upper_limit="-20.6"/>
                    <measurement group_id="O2" value="-18.9" lower_limit="-27.9" upper_limit="-9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Intermittent and Constant Osteoarthritis Pain (ICOAP) Constant Pain Subscale</title>
        <description>This 11-item tool is designed to assess pain in individuals with knee osteoarthritis taking into account both constant and intermittent pain experiences. This tool is designed to be interviewer-administered. Study participants are asked to respond to the questionnaire items based on index knee in the past week (i.e., past 7-day period). Study participants responded to all questions for the same joint. This tool is intended to be responsive to change in OA pain over time or with treatment. Range 0 to 100 mm. The higher the score, the worse the symptoms.</description>
        <time_frame>Baseline, week 24, week 48</time_frame>
        <population>Intent To Treat</population>
        <group_list>
          <group group_id="O1">
            <title>Sham</title>
            <description>Treatment to index knee with sham device for 48 weeks&#xD;
Sham Comparator: 20 minutes daily for 48 weeks</description>
          </group>
          <group group_id="O2">
            <title>PLIUS</title>
            <description>Treatment to index knee with PLIUS device for 48 weeks&#xD;
Pulsed Low Intensity Ultrasound: 20 minutes daily for 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Intermittent and Constant Osteoarthritis Pain (ICOAP) Constant Pain Subscale</title>
          <description>This 11-item tool is designed to assess pain in individuals with knee osteoarthritis taking into account both constant and intermittent pain experiences. This tool is designed to be interviewer-administered. Study participants are asked to respond to the questionnaire items based on index knee in the past week (i.e., past 7-day period). Study participants responded to all questions for the same joint. This tool is intended to be responsive to change in OA pain over time or with treatment. Range 0 to 100 mm. The higher the score, the worse the symptoms.</description>
          <population>Intent To Treat</population>
          <units>Visual Analog Scale (mm)</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from Baseline to Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.6" lower_limit="-20.1" upper_limit="9.1"/>
                    <measurement group_id="O2" value="-12.4" lower_limit="-18.0" upper_limit="-6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.4" lower_limit="-24.0" upper_limit="-12.8"/>
                    <measurement group_id="O2" value="-13.7" lower_limit="-20.7" upper_limit="-6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Intermittent and Constant Osteoarthritis Pain (ICOAP) Intermittent Pain Subscale</title>
        <description>This 11-item tool is designed to assess pain in individuals with knee osteoarthritis taking into account both constant and intermittent pain experiences. This tool is designed to be interviewer-administered and takes less than 10 minutes to complete. Study participants will be asked to respond to the questionnaire items based on index knee in the past week (i.e., past 7-day period). Study participants will respond to all questions for the same joint. This tool is intended to be responsive to change in OA pain over time or with treatment. Range 0 to 100 mm. The higher the score, the worse the symptoms.</description>
        <time_frame>Baseline, week 24, week 48</time_frame>
        <population>Intent To Treat</population>
        <group_list>
          <group group_id="O1">
            <title>Sham</title>
            <description>Treatment to index knee with sham device for 48 weeks&#xD;
Sham Comparator: 20 minutes daily for 48 weeks</description>
          </group>
          <group group_id="O2">
            <title>PLIUS</title>
            <description>Treatment to index knee with PLIUS device for 48 weeks&#xD;
Pulsed Low Intensity Ultrasound: 20 minutes daily for 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Intermittent and Constant Osteoarthritis Pain (ICOAP) Intermittent Pain Subscale</title>
          <description>This 11-item tool is designed to assess pain in individuals with knee osteoarthritis taking into account both constant and intermittent pain experiences. This tool is designed to be interviewer-administered and takes less than 10 minutes to complete. Study participants will be asked to respond to the questionnaire items based on index knee in the past week (i.e., past 7-day period). Study participants will respond to all questions for the same joint. This tool is intended to be responsive to change in OA pain over time or with treatment. Range 0 to 100 mm. The higher the score, the worse the symptoms.</description>
          <population>Intent To Treat</population>
          <units>Visual Analog Scale (mm)</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline to Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.7" lower_limit="-23.2" upper_limit="-12.3"/>
                    <measurement group_id="O2" value="-13.4" lower_limit="-18.2" upper_limit="-8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.2" lower_limit="-26.8" upper_limit="-13.6"/>
                    <measurement group_id="O2" value="-15.0" lower_limit="-21.5" upper_limit="-8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Intermittent and Constant Osteoarthritis Pain (ICOAP) Total Pain Score</title>
        <description>This 11-item tool is designed to assess pain in individuals with knee osteoarthritis taking into account both constant and intermittent pain experiences. This tool is designed to be interviewer-administered and takes less than 10 minutes to complete. Study participants will be asked to respond to the questionnaire items based on index knee in the past week (i.e., past 7-day period). Study participants will respond to all questions for the same joint. This tool is intended to be responsive to change in OA pain over time or with treatment. Range 0 to 100 mm. The higher the score, the worse the symptoms.</description>
        <time_frame>Baseline, week 24, week 48</time_frame>
        <population>Intent to Treat</population>
        <group_list>
          <group group_id="O1">
            <title>Sham</title>
            <description>Treatment to index knee with sham device for 48 weeks&#xD;
Sham Comparator: 20 minutes daily for 48 weeks</description>
          </group>
          <group group_id="O2">
            <title>PLIUS</title>
            <description>Treatment to index knee with PLIUS device for 48 weeks&#xD;
Pulsed Low Intensity Ultrasound: 20 minutes daily for 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Intermittent and Constant Osteoarthritis Pain (ICOAP) Total Pain Score</title>
          <description>This 11-item tool is designed to assess pain in individuals with knee osteoarthritis taking into account both constant and intermittent pain experiences. This tool is designed to be interviewer-administered and takes less than 10 minutes to complete. Study participants will be asked to respond to the questionnaire items based on index knee in the past week (i.e., past 7-day period). Study participants will respond to all questions for the same joint. This tool is intended to be responsive to change in OA pain over time or with treatment. Range 0 to 100 mm. The higher the score, the worse the symptoms.</description>
          <population>Intent to Treat</population>
          <units>Visual Analog Scale (mm)</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from Baseline to Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.3" lower_limit="-21.3" upper_limit="-11.3"/>
                    <measurement group_id="O2" value="-12.9" lower_limit="-17.9" upper_limit="-8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.4" lower_limit="-25.2" upper_limit="13.6"/>
                    <measurement group_id="O2" value="-14.4" lower_limit="-20.8" upper_limit="-7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Discontinuing the Study Device Due to an Adverse Device Event</title>
        <description>Difference between study groups in number of participants who discontinued usage of the study device due to adverse device events at 4, 8, 12, 24, 36, and 48-week visits.</description>
        <time_frame>Baseline, 4, 8, 12, 24, 36, and 48-week visits</time_frame>
        <population>Intent to Treat</population>
        <group_list>
          <group group_id="O1">
            <title>Sham</title>
            <description>Treatment to index knee with sham device for 48 weeks&#xD;
Sham Comparator: 20 minutes daily for 48 weeks</description>
          </group>
          <group group_id="O2">
            <title>PLIUS</title>
            <description>Treatment to index knee with PLIUS device for 48 weeks&#xD;
Pulsed Low Intensity Ultrasound: 20 minutes daily for 48 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Discontinuing the Study Device Due to an Adverse Device Event</title>
          <description>Difference between study groups in number of participants who discontinued usage of the study device due to adverse device events at 4, 8, 12, 24, 36, and 48-week visits.</description>
          <population>Intent to Treat</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Through study completion, an average of 48 weeks.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Sham</title>
          <description>Treatment to index knee with sham device for 48 weeks&#xD;
Sham Comparator: 20 minutes daily for 48 weeks</description>
        </group>
        <group group_id="E2">
          <title>PLIUS</title>
          <description>Treatment to index knee with PLIUS device for 48 weeks&#xD;
Pulsed Low Intensity Ultrasound: 20 minutes daily for 48 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (20.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina, Unstable</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Atrioventricular block, complete</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Ascitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Pharyngo-oesophageal diverticulum</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Alcohol Poisoning</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Lumbar radiculopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Shoulder arthroplasty</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Spinal laminectomy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Substance abuse</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Prostatectomy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Lipoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Dural arteriovenous fistula</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Daniel Clegg, MD</name_or_title>
      <organization>VA Salt Lake City Health Care System</organization>
      <phone>801-582-1565</phone>
      <email>daniel.clegg@va.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

